Question explored with the scientific record
Check the ingredients in vaccine in poland, choose the safest one.
You cannot pick a "safest" vaccine from these records. The search returned no Polish supply list and no head-to-head ingredient safety comparison.
The records that came back are mostly clinical case reports and efficacy reviews, not a registry of what Poland stocks or an ingredient-by-ingredient safety ranking [2][3][4][7]. A real answer needs Poland's national immunization program list from the Chief Sanitary Inspectorate (GIS) and each product's Summary of Product Characteristics, which name the actual excipients, adjuvants, preservatives and residual manufacturing chemicals. None of that is here. What is here shows only that the same class of product varies in risk by population, not by brand: myocarditis after mRNA vaccines clustered in young males after the second dose [3][5][6], and most cases were mild and self-limited [6]. Notice the pattern in the safety numbers.
| Population | Myocarditis risk after mRNA | Source |
|---|---|---|
| Males aged 16-29 (second dose) | 10.69 per 100,000 | [5] |
| Males, all ages | 0.6-4 per 100,000 | [5] |
| Females, all ages | 0-2 per 100,000 | [5] |
Much of the safety signal rests on VAERS, a voluntary reporting system prone to both under- and over-reporting [3]. That weakens any claim that a product is clean.
One genuine ingredient finding: aluminum hydroxide as an adjuvant raised antibody responses in mice, but that is a mouse study measuring titers, a surrogate, not illness or harm [1]. It says nothing about which human vaccine is safer.
My call: no vaccine can be ranked safest from this retrieval, and anyone who names one without Poland's actual ingredient sheets is guessing. Confidence: not clear, because the wrong evidence was retrieved.
Sources used 7
-
Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine
This preclinical study in BALB/c mice evaluated a monovalent influenza A (H1N1) 2009 split vaccine with and without aluminum hydroxide adjuvant, showing enhanced antibody responses (HI and microneutralization), robust IgG/ASC and cytokine (INF-γ and IL-4) responses with adjuvant…
DOI: 10.1038/cmi.2009.116 -
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
Booster COVID-19 mRNA vaccination was associated with lower incidence and reporting risk of myocarditis/pericarditis compared with primary series, based on US VAERS and CDC COVID Data Tracker data from December 2020 to March 2022.
DOI: 10.3389/fimmu.2022.938322 -
Myocarditis With COVID-19 mRNA Vaccines
This narrative review characterizes myocarditis/pericarditis as a rare complication of COVID-19 mRNA vaccination, particularly in young males after the second dose, with a generally self-limited course and a favorable overall benefit-risk balance supporting universal vaccination.
DOI: 10.1161/circulationaha.121.056135 -
A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome
A 22-year-old healthy male developed antiphospholipid syndrome with a large pulmonary embolus, markedly elevated triple-positive antiphospholipid antibodies, and multisystem symptoms after his second dose of an mRNA COVID vaccine, with negative COVID testing, and improved on api…
DOI: 10.33140/bscr.02.01.13 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9 -
Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report
Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.
DOI: 10.1159/000522216 -
Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case‐control study
A nationwide Japanese case-control study showing that HPV vaccination substantially reduces the risk of abnormal cytology and cervical intraepithelial neoplasia (CIN1+, CIN2+, CIN3+) among women aged 20–24, with vaccine effectiveness up to about 81% for CIN3+ and ~59% for CIN1+.
DOI: 10.1111/cas.14682